distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and redistribution in any medium, provided that the original author and source are credited. 4 . What in vivo models has this been tested in? The paper you linked only mentions cell culture experiments.
SirT6
1. The actual number of infected cells generally appears to be quite small, so we hope that DRACO can be used without any harmful effects, or at least no more damage than the viruses would have caused. We have done a number of experiments in mice and seen good efficacy against the viruses with which we had infected the mice, but no apparent toxicity otherwise. The mice appeared healthy and active while alive, even with daily doses of DRACO, and appeared to remain normal even after several weeks. We performed necropsies on a number of mice at various time points after they had received large DRACO doses and saw no apparent tissue damage in any organs. Although we tried to prevent the mice from coming into contact with viruses other than those we were testing, these were large colonies of your average lab mice and likely had other viruses, yet DRACO did not appear to cause any problems. We hope that will continue to hold true in future animal trials, and hopefully in human trials ultimately, though of course we will not know for certain until we do the experiments. In our mouse trials we also found that DRACO could be preferentially targeted to certain tissues with the right delivery tags and administration methods, so if necessary, DRACO could be targeted toward the intended infected tissues and not toward other tissues if that proves desirable.
2. Most ERVs have been inactivated or nearly inactivated by accumulated mutations, and they generally do not appear to be producing long double-stranded RNA (dsRNA), which is why cellular defense proteins have been optimized to look for that to distinguish invading viruses from normal cellular processes. DRACO is based on those natural cellular defense proteins, so in theory it should not harm otherwise uninfected cells. In our experiments thus far, DRACO appears to be nontoxic in a wide variety of human and animal cell types, and also in live mice.
3. You are quite correct that Ebola and some other viruses try to hide their dsRNA to avoid activating cellular defense proteins such as PKR. Several of the viruses against which we have already tested DRACO had similar dsRNA countermeasures, yet DRACO was effective against all of them. Currently my best explanation is that the viral countermeasures may be sufficient to inhibit the more modest interferon and inflammatory responses that natural cellular proteins try to initiate, but may not be sufficiently effective to inhibit the rapid apoptosis initiated by DRACO. If we do encounter viruses that are more resistant, we have a variety of different DRACO designs that could be used to overcome that resistance. In general, newly evolved resistance is much more likely with highly specific therapeutics, where the virus can slightly mutate the structure targeted by that therapeutic, and should be less of a problem for very broad-spectrum therapeutics such as DRACO.
4. As shown in our PLoS ONE paper, we have done a number of successful trials in BALB/c mice. As discussed in the online SENS presentation and presentations we have given at American Society for Microbiology and other conferences, we have also successfully tested DRACO in AG129 mice. If we can test and optimize DRACOs against herpesviruses in cells, we would love to move on to test in rodent models of herpesviruses too.
The DRACO strategy relies on getting large proteins into cells in a human being. This is an incredibly difficult endeavor, and the strategy applied in your PLoS One paper (transduction tags) has never succeeded in a clinical setting. How do you plan to achieve intracellular protein delivery in vivo, and why do you think everyone else has been unable to do this?
Wackademic
Delivering protein therapeutics inside cells is fairly new, so it is not surprising that therapeutics using that approach are not already being used clinically in humans. However, in addition to DRACO, there You occasionally mention that it would be difficult for viruses to evolve resistance to DRACOs. Given that many viruses have mechanisms to sequester dsRNA away from the cell's dsRNA sensing pathways (for example, the poxvirus E3L dsRNA binding protein used in some of the DRACO constructs), it seems likely to me that such viruses would find it fairly easy to increase resistance to DRACOs, perhaps by increasing expression or affinity of their dsRNA binding proteins. Do you think this couldn't happen, and if so, why?
zmil You are quite right that some other viruses try to hide their dsRNA to avoid activating cellular defense proteins such as PKR. Several of the viruses against which we have already tested DRACO had similar dsRNA countermeasures, yet DRACO was effective against all of them. Currently my best explanation is that the viral countermeasures may be sufficient to inhibit the more modest interferon and inflammatory responses that natural cellular proteins try to initiate, but may not be sufficiently effective to inhibit the rapid apoptosis initiated by DRACO. If we do encounter viruses that are more resistant, we have a variety of different DRACO designs that could be used to overcome that resistance. In general, newly evolved resistance is much more likely with highly specific therapeutics, where the virus can slightly mutate the structure targeted by that therapeutic, and should be less of a problem for very broad-spectrum therapeutics such as DRACO.
Hello there, i really do think it's high time more innovative and translational approaches are used to address medical issues. I've had my heart set on this ever since i entered med school and now that I'm finished I'm looking into doing a PhD in molecular biology or immunology or other domains with problem-solving potential. How hard would it be for an MD. to break into this field(I'm referring to the engineering part which i like but have no training in)?
Lecsicon
There are many people working in this general field with just an M.D., just a Ph.D., or both. Congratulations on finishing medical school and for wanting to really make a difference, and good luck with your career! Will we soon to be able to cure virus induced diseases as "easily" as bacteria induced diseases (due to the related antibiotics)? Will we be able to cure a normal cold or influence in a day or two? Jadeyard I believe DRACO has the potential to revolutionize the treatment and prevention of viral infections, just as antibiotics previously revolutionized the treatment and prevention of bacterial infections. We have already shown that DRACO is effective against rhinoviruses (common cold viruses) in cells, and effective against influenza (flu) viruses both in cells and in mice. If we can raise enough support on IndieGoGo, we plan to continue to develop and demonstrate DRACO therapeutics. I really hope to see them advance toward human trials ultimately. As a medical student I would like to say that your work is nothing short of amazing. Keep it up!! BaghdadBeauties Thank you very much for your support, and good luck with your studies! I was wondering if there is resistance to fund something which cures as opposed to something which people will have to take for the rest of their lives. When I first heard about DRACO I naturally assumed I would never hear about it again because curing disease doesn't seem as profitable as chronic disease management.
Rumpel_Tumskin
A number of people have wondered about that, but I have not seen any evidence thus far that that is actually a problem. The resistance to DRACO and other new approaches that I have seen seems to arise because those approaches are so novel, not because they might be so effective. In my opinion, industrial and government sponsors have become much more averse to more novel, riskier, and/or longer-term scientific development, opting instead for relatively minor variations on existing approaches such as vaccines, nucleoside/nucleotide analogues, etc. And those existing approaches generally do have real limitations.
Hi,
How much money would it cost to produce Dracos at a large industrial scale ? How much will they cost when they re going to enter the market ?
Linux1337Hexxor
The ultimate cost per dose for DRACO treatment, if it is eventually approved for human use, will be determined many years down the road and by many factors, including the cost to scale up and consistently produce very high-quality DRACO batches, the amount of DRACO required for efficacy, the costs of large-scale animal and human trials, the number of users over which those costs can be spread, and many other factors. I certainly want DRACO to benefit as many people as possible and hope to do whatever I can to keep the final cost as low as possible.
Hi Dr. Rider, my boss here in Germany has been trying to get in touch with you since the summer RE: possibly using DRACO technology for treatment. What is the best way to get in touch with you privately? (In case you were wondering, your old MIT and Draper lab email accounts that show up on I understand it's only been tested on lab animals yet. Could the current version work for humans too, or are there still unsolved challenges?
Could it be a cure for HIV?
When is the earliest it may be available for humans, assuming all goes well?
Minthos
We have a number of DRACO designs and approaches but do not currently know which if any would be effective against major clinically relevant viruses such as herpesviruses and retroviruses. The fastest, cheapest, and safest path forward is to test and optimize DRACOs against clinically relevant virus families in cells. If we can successfully obtain such data in cells, we believe those results should persuade pharmaceutical companies to carry DRACOs through large-scale animal trials and hopefully into human trials. The timeline depends on funding levels (including how much funding pharmaceutical companies are willing to commit later) and whether any unforeseen scientific difficulties arise in the experiments. However, if everything goes well, we hope that DRACO could enter human trials within a decade or even less.
Hi, I've read that your PhD was actually in electrical engineering and computer science, and your doctoral thesis addressed the question of energy consumption and radiation emissions from hot fusion reactors. My question is, how have you been able to transition from engineering, and physics into biology? Did you take grad courses in biology, or did you achieve this through self study? The idea that one can get a PhD in a certain field, and subsequently do research in a completely unrelated field is inspiring given the highly specialized and constricting nature of modern scientific disciplines. 
